Free Trial
NASDAQ:SOPH

SOPHiA GENETICS (SOPH) Stock Price, News & Analysis

SOPHiA GENETICS logo
$3.05 -0.01 (-0.33%)
As of 04:00 PM Eastern

About SOPHiA GENETICS Stock (NASDAQ:SOPH)

Key Stats

Today's Range
$3.03
$3.11
50-Day Range
$2.66
$4.88
52-Week Range
$2.58
$6.28
Volume
5,999 shs
Average Volume
64,730 shs
Market Capitalization
$203.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.80
Consensus Rating
Moderate Buy

Company Overview

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.

SOPHiA GENETICS Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
28th Percentile Overall Score

SOPH MarketRank™: 

SOPHiA GENETICS scored higher than 28% of companies evaluated by MarketBeat, and ranked 503rd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    SOPHiA GENETICS has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    SOPHiA GENETICS has received no research coverage in the past 90 days.

  • Read more about SOPHiA GENETICS's stock forecast and price target.
  • Earnings Growth

    Earnings for SOPHiA GENETICS are expected to grow in the coming year, from ($0.96) to ($0.81) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of SOPHiA GENETICS is -2.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of SOPHiA GENETICS is -2.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about SOPHiA GENETICS's valuation and earnings.
  • Percentage of Shares Shorted

    0.10% of the float of SOPHiA GENETICS has been sold short.
  • Short Interest Ratio / Days to Cover

    SOPHiA GENETICS has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in SOPHiA GENETICS has recently increased by 4.12%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    SOPHiA GENETICS does not currently pay a dividend.

  • Dividend Growth

    SOPHiA GENETICS does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.10% of the float of SOPHiA GENETICS has been sold short.
  • Short Interest Ratio / Days to Cover

    SOPHiA GENETICS has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in SOPHiA GENETICS has recently increased by 4.12%, indicating that investor sentiment is decreasing.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for SOPHiA GENETICS this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    1 people have added SOPHiA GENETICS to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, SOPHiA GENETICS insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.88% of the stock of SOPHiA GENETICS is held by insiders.

  • Percentage Held by Institutions

    Only 31.59% of the stock of SOPHiA GENETICS is held by institutions.

  • Read more about SOPHiA GENETICS's insider trading history.
Receive SOPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SOPHiA GENETICS and its competitors with MarketBeat's FREE daily newsletter.

SOPH Stock News Headlines

Sophia Genetics, Precision for Medicine enter strategic partnership
Top Picks for Trump’s Pro-Crypto America
Just Announced: What Trump’s Move Means for Crypto—Join Now 27 top names reveal urgent insights as Bitcoin rebounds
Morgan Stanley Keeps Their Hold Rating on SOPHiA GENETICS (SOPH)
SOPHiA GENETICS (SOPH) Gets a Buy from BTIG
SOPHiA GENETICS (SOPH) Receives a Buy from BTIG
See More Headlines

SOPH Stock Analysis - Frequently Asked Questions

SOPHiA GENETICS's stock was trading at $3.07 at the beginning of the year. Since then, SOPH shares have decreased by 0.7% and is now trading at $3.05.
View the best growth stocks for 2025 here
.

SOPHiA GENETICS SA (NASDAQ:SOPH) released its quarterly earnings data on Tuesday, March, 4th. The company reported ($0.23) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.23). The company had revenue of $17.73 million for the quarter, compared to analyst estimates of $17.71 million. SOPHiA GENETICS had a negative trailing twelve-month return on equity of 55.06% and a negative net margin of 110.71%.
Read the conference call transcript
.

SOPHiA GENETICS (SOPH) raised $234 million in an IPO on Friday, July 23rd 2021. The company issued 13,000,000 shares at a price of $17.00-$19.00 per share.

Top institutional investors of SOPHiA GENETICS include Bank Pictet & Cie Europe AG (0.38%) and Silverberg Bernstein Capital Management LLC (0.05%).

Shares of SOPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that SOPHiA GENETICS investors own include Occidental Petroleum (OXY), PayPal (PYPL), Chesapeake Energy (CHK), Cheniere Energy (LNG), Rocket Pharmaceuticals (RCKT), AbCellera Biologics (ABCL) and Farmers & Merchants Bancorp (FMAO).

Company Calendar

Last Earnings
3/04/2025
Today
4/24/2025
Next Earnings (Estimated)
5/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SOPH
Fax
N/A
Employees
520
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.80
High Stock Price Target
$11.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+119.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-78,980,000.00
Net Margins
-110.71%
Pretax Margin
-109.76%

Debt

Sales & Book Value

Annual Sales
$65.17 million
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
62,185,000
Market Cap
$207.06 million
Optionable
Not Optionable
Beta
1.02
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:SOPH) was last updated on 4/24/2025 by MarketBeat.com Staff
From Our Partners